Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

doi:10.1111/ejh.70164

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.

European journal of haematology - 1 Aug 2026

Song Lin, Wei Xudong, Zhai Zhimin, Wang Anyou, Jiang Daozi, Liang Yang, Li Fei, Jiang Zhongxing, Zhang Xuejun, Guo Qunyi, Jing Hongmei, Xu Yajing, Tong Xiangmin, Wang Jianmin, Wang Jianxiang, Qi Junyuan

Abstract excerpt

This Phase I/II clinical trial (NCT04471064) evaluated the preliminary efficacy, safety, and pharmacokinetics of XY0206, a novel oral FMS-like tyrosine kinase 3 (FLT3) inhibitor, in patients with relapsed or refractory acute myeloid leukemia (R/R AML). From September 2020 to December 2022, this open-label, multicenter study enrolled patients aged ≥ 18 years with R/R AML. The trial included dose-escalation and...

Topics

Humans
fms-Like Tyrosine Kinase 3
Leukemia, Myeloid, Acute
Female
Middle Aged
Aged
Protein Kinase Inhibitors
Male
Adult
Recurrence

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Treatment Outcome

Mutation

Aged, 80 and over

Drug Resistance, Neoplasm

Antineoplastic Agents

Young Adult

Remission Induction

Source

Open in PubMed

Identifiers

PMID: 42015516
DOI: 10.1111/ejh.70164

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 29 Aug 2026. Prepared record publication-42015516-2026-08-29.1. Manifest publication-graph-cohort-2026-08-29.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 29 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients With Relapsed/Refractory Acute Myeloid Leukemia.PMID 42015516Read ↗

A systematic review of second-generation FLT3 inhibitors for treatment of patients with relapsed/refractory acute myeloid leukemia.Semantic proximity Read ↗

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review.Semantic proximity Read ↗

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions.Semantic proximity Read ↗

FLT3 inhibitors: clinical potential in acute myeloid leukemiaSemantic proximity Read ↗

Characteristics and Outcome of FLT3-ITD-Positive Acute Myeloid Leukemia.Semantic proximity Read ↗

Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia - Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis.Semantic proximity Read ↗

[Current status and challenges of AML treatment with FLT3 inhibitors].Semantic proximity Read ↗

FMS-Like Tyrosine Kinase 3 Inhibitors for the Treatment of Acute Myeloid Leukemia.Semantic proximity Read ↗

[Breakthroughs in FLT3-mutated acute myeloid leukemia treatments].Semantic proximity Read ↗

Quizartinib: a new hope in acute myeloid leukemia, an applied comprehensive review.Semantic proximity Read ↗

Safety of FLT3 inhibitors in patients with acute myeloid leukemia.Semantic proximity Read ↗

FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.